POHERDY
LaunchmAbpertuzumab-dpzb
BLAINTRAVENOUSINJECTABLE
Approved
Nov 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POHERDY (pertuzumab-dpzb) is a monoclonal antibody biosimilar approved in November 2025 as an intravenous injectable. It is a reference-product biosimilar with the same mechanism of action as the originator pertuzumab. The specific indications and mechanism of action are not yet detailed in available data.
Launch
As a newly approved biosimilar entering a mature oncology market, this product presents a launch-phase opportunity with moderate competitive pressure (30) but limited immediate commercial data.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on POHERDY at launch offers exposure to biosimilar commercialization in a competitive oncology space with moderate near-term growth potential. Career development will center on market penetration strategy, payer relationships, and competing against established reference and biosimilar products.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.